ArticlePloS one2017
Gallium nanoparticles facilitate phagosome maturation and inhibit growth of virulent Mycobacterium tuberculosis in macrophages.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- Actively Targeted Nanoparticles for Enhanced Diagnosis, Treatment, and Vaccination of Tuberculosis: A Systematic Review.International journal of nanomedicine · 2025Pooled it
- Fullerene Gallium Phosphonate Shows Antimycobacterial Effect AgainstInternational journal of molecular sciences · 2025Article
- Applications of Inorganic Nanomaterials against Tuberculosis: A Comprehensive Review.Current drug delivery · 2025Review
- Mannosamine-Engineered Nanoparticles for Precision Rifapentine Delivery to Macrophages: Advancing Targeted Therapy Against Mycobacterium Tuberculosis.Drug design, development and therapy · 2025Article
- Efficacy and Possible Mechanism(s) of Action of Gallium Tetraphenylporphyrin Nanoparticles against HIV-TB Coinfection in anACS infectious diseases · 2024Article
- A comprehensive review of paratuberculosis in animals and its implications for public health.Open veterinary journal · 2024Review
- Gallium: a decisive "Trojan Horse" against microorganisms.Antonie van Leeuwenhoek · 2024Review
- Investigating Novel IspE Inhibitors of the MEP Pathway in Mycobacterium.Microorganisms · 2023Article
- Micro-nanoemulsion and nanoparticle-assisted drug delivery against drug-resistant tuberculosis: recent developments.Clinical microbiology reviews · 2023Review
- A Current Perspective on the Potential of Nanomedicine for Anti-Tuberculosis Therapy.Tropical medicine and infectious disease · 2023Review
- Gallium-Based Liquid Metal Materials for Antimicrobial Applications.Bioengineering (Basel, Switzerland) · 2022Review
- Recent Developments in Drug Delivery for Treatment of Tuberculosis by Targeting Macrophages.Advanced therapeutics · 2022Article
- Advancement of Gallium and Gallium-Based Compounds as Antimicrobial Agents.Frontiers in bioengineering and biotechnology · 2022Review
- Cathepsin D-Managing the Delicate Balance.Pharmaceutics · 2021Review
- Advances in Plasmonic Sensing at the NIR-A Review.Sensors (Basel, Switzerland) · 2021Review
- Pulling the Brakes on Fast and Furious Multiple Drug-Resistant (MDR) Bacteria.International journal of molecular sciences · 2021Review
- Approaches to treating tuberculosis by encapsulating metal ions and anti-mycobacterial drugs utilizing nano- and microparticle technologies.Emerging topics in life sciences · 2020Review
- The Role of Metallic Nanoparticles in Inhibition of Mycobacterium Tuberculosis and Enhances Phagosome Maturation into the Infected Macrophage.Oman medical journal · 2020Review
- Metal-Peptide Complexes as Promising Antibiotics to Fight Emerging Drug Resistance: New Perspectives in Tuberculosis.Antibiotics (Basel, Switzerland) · 2020Review
- Multi-functionalized nanocarriers targeting bacterial reservoirs to overcome challenges of multi drug-resistance.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
New treatments and novel drugs are required to counter the growing problem of drug-resistant strains of Mycobacterium tuberculosis (M.tb). Our approach against drug resistant M.tb, as well as other intracellular pathogens, is by targeted drug delivery using nanoformulations of drugs already in use, as well as drugs in development. Among the latter are gallium (III) (Ga)-based compounds. In the current work, six different types of Ga and rifampin nanoparticles were prepared in such a way as to enhance targeting of M.tb infected-macrophages. They were then tested for their ability to inhibit growth of a fully pathogenic strain (H37Rv) or a non-pathogenic strain (H37Ra) of M.tb. Encapsulating Ga in folate- or mannose-conjugated block copolymers provided sustained Ga release for 15 days and significantly inhibited M.tb growth in human monocyte-derived macrophages. Nanoformulations with dendrimers encapsulating Ga or rifampin also showed promising anti-tuberculous activity. The nanoparticles co-localized with M.tb containing phagosomes, as measured by detection of mature cathepsin D (34 kDa, lysosomal hydrogenase). They also promoted maturation of the phagosome, which would be expected to increase macrophage-mediated killing of the organism. Delivery of Ga or rifampin in the form of nanoparticles to macrophages offers a promising approach for the development of new therapeutic anti-tuberculous drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.